Form 8-K NEUROCRINE BIOSCIENCES For: Jan 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Futures point to higher open as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Neurocrine Bio. (NBIX) PT Lowered to $122 at RBC Capital Following Ingrezza Sales Data
January 7, 2022 7:44 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $122.00 (from $125.00) while maintaining an Outperform rating following Q4 Ingrezza sales that missed slightly due to greater discounting.
The analyst commented, "NBIX's pre-reported 4Q21 Ingrezza sales miss is slightly disappointing,... More
